Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a β3‑adrenoceptor agonist presented as a tablet for oral use. It relaxes the detrusor muscle of the urinary bladder, increasing capacity and reducing symptoms of overactive bladder such as urgency, frequency, and urge incontinence in adult patients.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution, with full traceability and batch‑release documentation.

Mirabegron is indicated for conditions related to overactive bladder, a disorder characterized by involuntary detrusor contractions.

- Overactive bladder: reduces urgency episodes and increases bladder capacity. - Urinary urgency: improves control over sudden urges to void. - Urinary frequency: decreases daytime voiding frequency.

Adverse reactions reported with mirabegron can be grouped by frequency.

Common Side Effects: - Increased blood pressure: mild elevations observed in some patients. - Nasopharyngitis: upper respiratory tract infection symptoms. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Hypertension: significant rise in blood pressure requiring medical attention. - Urinary retention: difficulty initiating or maintaining urine flow. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing mirabegron, clinicians should consider several precautionary measures.

- Blood pressure monitoring: check baseline and periodically during therapy. - Cardiovascular assessment: evaluate patients with known heart disease before initiating. - Renal function evaluation: adjust use in severe renal impairment. - Concomitant β‑agonists: avoid combining with other β‑adrenergic agents without supervision. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mirabegron may interact with other medicines, altering their plasma concentrations or pharmacodynamic effects.

Major Interactions (Avoid): - CYP2D6 substrates (e.g., metoprolol): increased exposure; may require dose reduction. - Antihypertensives (e.g., ACE inhibitors): additive blood pressure effects; monitor closely.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise mirabegron levels. - Diuretics: enhanced risk of hypertension. - Anticholinergics: potential additive urinary retention.